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Reactive oxygen species (ROS) and autophagy are two highly complex and interrelated components of cell physiopathology, but
our understanding of their integration and their contribution to cell homeostasis and disease is still limited. Sestrins (SESNs)
belong to a family of highly conserved stress-inducible proteins that orchestrate antioxidant and autophagy-regulating
functions protecting cells from various noxious stimuli, including DNA damage, oxidative stress, hypoxia, and metabolic stress.
They are also relevant modulators of metabolism as positive regulators of the key energy sensor AMP-dependent protein
kinase (AMPK) and inhibitors of mammalian target of rapamycin complex 1 (mTORC1). Since perturbations in these
pathways are central to multiple disorders, SESNs might constitute potential novel therapeutic targets of broad interest. In this
review, we discuss the current understanding of regulatory and eﬀector networks of SESNs, highlighting their signiﬁcance as
potential biomarkers and therapeutic targets for diﬀerent diseases, such as aging-related diseases, metabolic disorders,
neurodegenerative diseases, and cancer.
1. Introduction
Reactive oxygen species (ROS) can play essential roles as
intra- and extracellular messengers, encoding the functio-
nal/metabolic state of the cell for the regulation of numerous
signalling pathways. However, ROS are also powerful oxidiz-
ing agents, which can induce cell injury upon modiﬁcation of
lipids, proteins, or DNA, disrupting cell function and
increasing the risk of DNAmutation and tumorigenesis. Oxi-
dation of speciﬁc amino acid residues in diﬀerent metabolic
enzyme systems (such as the 2-oxoglutarate dehydrogenase
complex in the tricarboxylic acid cycle) can alter their activity
by orders of magnitude, completely changing cell sensitivity
to other environmental conditions, such as fuel availability
or usage of nutrients [1]. Thus, aberrant ROS levels are a con-
sequence shared by a broad list of pathologies, and ROS dys-
regulation substantially drives the onset and progression of a
number of diseases. For example, high ROS levels found in
most cancer cells can promote metabolic rewiring and
growth dysregulation, as well as aberrant response of cells
to diﬀerent challenges by gating the activation threshold of
apoptosis, necrosis, or autophagic death. Analogies can
thereby be drawn for aging biology. As such, intervention
of ROS levels has received substantial attention as a potential
antiaging and anticancer therapeutic opportunity, including
it in the renewed study of strategies, such as diﬀerential
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ascorbate toxicity [2–4]. Conversely, ROS deﬁciency has been
associated mechanistically with immune disorders, inﬂam-
mation, and decreased proliferative response, partly because
of the disruption of cell signalling wiring [5].
A major theme in ROS-associated disorders is their
interplay with systems determining energy and nutrient
homeostasis in the cell. The mechanistic target of rapamy-
cin complex 1 (mTORC1) and 5′ AMP-activated protein
kinase (AMPK) interpret multiple cues, including oxidative
stress, to integrate them with the control of energy man-
agement, anabolism, and cell growth. Conversely, these sig-
nalling systems regulate metabolism and growth, which are
major ROS sources themselves. These pathways, together
with other stress signalling routes such as the Unfolded
Protein Response (UPR), tightly regulate the autophagy
ﬂux, a key node for both the regulation of ROS levels
and ROS-dependent cell regulation. This recycling func-
tion curbs ROS overproduction and, through a number
of input pathways, is itself sensitive to existing ROS levels
in the cell.
However, our understanding of the interplay between
these two aspects of cell physiology (ROS and autophagy)
is still limited. In this review, we aim to provide an over-
view of our current knowledge on sestrins (SESNs), a fam-
ily of stress surveillance proteins which may hold a key to
the integration of ROS control and autophagy regulation
and may constitute an interesting source of novel therapeu-
tic opportunities.
2. The Sestrin Protein Family
SESNs are a family of proteins induced upon various stres-
sing conditions, such as hypoxia and metabolic imbalances
[6]. Only one member is present in invertebrates (such as
Caenorhabditis elegans (cSESN) and Drosophila melanoga-
ster (dSESN), whereas three members are present in mam-
mals, such as SESN1, SESN2, and SESN3. Vertebrate
SESN1 (also known as PA26) is a transcriptional target of
p53 [7]. SESN2 (also known as H195) was discovered as a
gene activated by hypoxia [8]. The SESN3 gene is a largely
uncharacterized open reading frame identiﬁed by homology
[8]. Curiously, SESNs were named SESNs after a human
genetics course held in Sestri Levante, a small town on the
Ligurian coast of Italy, where researchers discovered the
amino acid sequence homology between the three proteins
[9]. Intriguingly, although they have close homology and
likely common origin, each SESN gene maps to a diﬀerent
chromosome in the human genome: SESN1 to 6q21, SESN2
to 1p35.3, and SESN3 to 11q21 [8].
2.1. Structure-Function Relationships and Interactomes of
SESNs. While phenotypic and pathophysiological associa-
tions for SESNs rapidly accumulated, information about
their molecular underpinnings has been scarce. Inference
from in silico studies has been limited by the fact that these
proteins do not contain obvious similarity with any known
structural domain or catalytic motif [6].
Recently, the determination of the human SESN2 struc-
ture by X-ray crystallography brought a novel insight into
its potential function. The crystal structure revealed that
hSESN2 contains two structurally similar subdomains,
SESN-AandSESN-C, connected by ahelix-loop-helix domain
(SESN-B). Both subdomains share signiﬁcant homology with
proteins belonging to the alkyl hydroperoxidase family
(including, for example,M. tuberculosis AhpD), which catal-
yse the reduction of peroxiredoxins [10, 11]. Alkyl hydroper-
oxidase activity has been conﬁrmed for SESN2 (as reported
below), while no biochemical characterization has so far been
gathered for SESN1 and SESN3.
Multiple protein-protein interactions mediate activation,
modulation, and function of SESNs [12]. In particular,
analysis of the SESN2 structure allows the identiﬁcation of
three functional domains [10, 11]. An oxidoreductase active
site within SESN-A, which contains the catalytic cysteine
(C125) and conserved residues of the proton relay system
(Y127 and H132), has been identiﬁed. These three amino
acid residues were found to be critical for the antioxidant
function of hSESN2. Although structural and biochemical
evidence demonstrates that hSESN2 has intrinsic peroxidase
activity, the physiological ROS substrate of hSESN2 remains
to be identiﬁed. Secondly, a GATOR2-interacting surface
at the C-terminal domain, containing a characteristic
aspartate-aspartate (DD) motif, has been mapped. This
DD motif appears to be required for the interaction
between hSESN2 and GATOR2. The heteropentameric
GATOR2 complex is a direct physical target of SESNs
and mediates its mTORC1-regulating functions.
Finally, a leucine-binding site is present in the SESN-C
domain. The existence of this leucine-binding site suggests
that hSESN2 acts as a direct cellular sensor of leucine level,
which is a relevant feature considering that leucine is a key
amino acid for the lysosome-mTORC1 system to sense over-
all levels of amino acid nutrients [13].
Importantly, SESN2 also interacts with Kelch-like ECH-
associated protein 1 (Keap1) and the autophagy regulators
p62/sequestosome-1 (SQSTM1) and Unc51-like 1 (ULK1).
These interactions likely underpin a substantial share of the
impact of SESN2 on the suppression of oxidative damage
and on autophagy regulation respectively, as detailed below
(Figure 1).
2.2. Regulation of Expression and Function of SESNs. SESNs
are proteins ubiquitously expressed in adults, although there
exist tissue-speciﬁc variations in gene expression levels [7–9].
Interestingly, SESN1 and SESN2 are most highly expressed in
skeletal muscle [7], a feature shared only by the Drosophila
homolog, dSESN [14]. dSESN expression increases with
aging [14], while expression of SESNs in humans is reduced
in individuals of advanced age [15].
As a family of stress-inducible proteins, SESNs have been
reported to be upregulated and activated upon exposure to
DNA damage, oxidative stress, and hypoxia. Whereas SESN1
and SESN2 are mainly responsive to p53 [7, 8], SESN3 is acti-
vated by forkhead box O (FoxO) transcriptional factors [16].
Other transcription factors responsible for the expression of
SESNs include nuclear factor erythroid 2-like 2 (Nrf2) [17],
NH(2)-terminal kinase (JNK)/c-Jun pathway [18], and
hypoxia-inducible factor-1α (HIF-1α) [19].
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Diﬀerent stimuli modulate the SESN phosphorylation
state, a key aspect of SESN regulation. Multiple phosphor-
acceptor sites have been found in dSESN in vivo in Drosoph-
ila [20]. In humans, regulation by phosphorylation has been
characterized mainly for the SESN2 paralog. Mass spectrom-
etry analysis of human SESN2 revealed three highly con-
served phosphorylation sites. Importantly, mutation of
these sites to phosphor-mimetic amino acids in exogenously
expressed SESN2 promoted its interaction with GATOR2
and dramatically repressed mTORC1 [21]. This supports a
potential relevance for SESN2 phosphorylation in the nega-
tive regulation of mTOR to prevent age-related pathologies
caused by chronic mTOR activation.
3. SESN2 in Antioxidant Defence
SESNs promote antioxidant adaptive responses in cells as
induced upon intracellular oxidative stress by the stimulation
of transcription factors, such as p53, Nrf2, AP-1, and FoxOs
(Figure 2). SESN1 is induced by hydrogen peroxide in a
p53-dependent manner, whereas the induction of SESN2
by oxidative stress is only partially dependent on p53 acti-
vation [22]. SESN2 can be induced in conditions of
increased ROS production, in a CCAAT/enhancer binding
protein-beta- (C/EBPβ-) dependent manner [23]. More
recently, oxidative stress was found to induce SESN2 via
activation of the transcription factor Nrf2 [17] and via the
JNK/AP-1 signalling axis [18], while SESN3 is stimulated
by oxidative damage via activation of FoxO transcription
factors [24, 25]. Consistent with a relevant contribution of
SESNs in the cellular antioxidant defence, silencing of all
the three SESN isoforms blunts the antioxidant response
to diﬀerent oxidative stress challenges [16, 26], whereas
ectopic expression of SESNs has a protective impact. How-
ever, the molecular underpinnings of this activity are still
incompletely clear.
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Figure 1: (a) Schematic diagram of full-length SESN2 showing the three domains SESN-A, SESN-B, and SESN-C. (b) Schematic
representation of SESN2 showing the localization of the catalytic cysteine (C125) and conserved residues of the proton relay system (Y127
and H132) in the SESN-A domain, the characteristic aspartate-aspartate (DD) motif, and the Leu binding site in the SESN-C domain
(based on structure analysis published by Ho et al. in reference [12], Figure 1, doi:10.1016/j.tibs.2016.04.005). (c) Schematic representation
of SESN2 showing direct interactors and pathways involved.
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As mentioned above, the oxidoreductase active site
within SESN-A is critical for the antioxidant function of
hSESN2. While structural and biochemical evidence demon-
strates that hSESN2 has intrinsic peroxidase activity, the
physiological ROS substrate(s) of hSESN2 is (are) currently
unknown. Hydrogen peroxide, which is among the most
abundant and biologically signiﬁcant cellular ROS species,
is not eﬃciently reduced by hSESN2, and the only known
substrate under in vitro conditions for hSESN2 is cumene
hydroperoxide, which is not a physiological ROS in any
known cell type [10].
Since a small conserved region in SESNs shows a limited
sequence homology to AhpD protein of Mycobacterium
tuberculosis [26], this similarity was analyzed for its ability
to reduce known substrates of AhpD, such as peroxiredoxin
(Prx). SESNs can indeed reduce Prx, but intriguingly this
does not require their catalytic activity [27]. It was hypothe-
sized that SESNs may promote the activity of other oxidore-
ductases, such as sulforedoxin (Srx), that in turn can
regenerate Prx. Indeed, one recent study showed that SESNs
can increase Srx expression through positive feedback activa-
tion of Nrf2, a transcription factor that orchestrates antioxi-
dant responses [28].
Independent of their Prx-regulating activity, SESNs con-
tribute to cell redox homeostasis through the regulation of
AMPK-mTORC1 signalling pathways. dSESN-/- Drosophila
cells exhibit increased TOR activity [14]. Since mTOR activ-
ity may enhance ROS production via inhibition of autophagy
or directly acting on mitochondrial function, a relevant share
of the antioxidant role of SESNs may be derived from mTOR
signalling inhibition.
4. SESNs as Regulators of Autophagy
and Mitophagy
The term “autophagy” refers to a group of regulated mecha-
nisms by which cells break down speciﬁc building blocks and
structures, enabling their recycling, the rerouting of their
energy, or their disposal when they are damaged and/or toxic
[29]. While a number of pathway variants exist, the core
machinery and the regulatory cascade its components map
to are rather deﬁned and evolutionarily conserved [29]. The
Unc51-like kinases ULK1/2 are major phosphor-regulated
initiator switches of the pathway, tightly controlled by posi-
tive growth signalling [30]. Their dephosphorylation triggers
the nucleation of the phagophore, the precursory membrane
structure from which the autophagic vesicle is formed, by a
Vps14/Beclin1/Atg14L complex [31]. This event initiates a
signalling cascade that accumulates PE-conjugated Atg8,
which drives the maturation and closure of autophagosomes,
enabling the docking of speciﬁc cargos and adaptor proteins,
such as sequestosome-1/p62 [32]. The fusion of the autopha-
gosome with the lysosomal compartment is mediated by
multiple proteins, including SNAREs and UVRAG [33].
Autophagy is tightly linked to ROS control in the cell [34].
Mitophagy is a specialized form of autophagy by which
dysfunctional or damaged mitochondria are selectively tar-
geted by autophagosomes and delivered to lysosomes to be
recycled by the cell. Hence, mitophagy represents an essential
quality control mechanism to ensure the integrity and func-
tionality of the mitochondrial network [35]. Dysregulation
of mitophagy leads to unresolved damage to mitochondria,
a powerful source for pathological ROS levels [36]. High
ROS
Antioxidant defences
Aging Age-related diseases
Oncogenic Cytotoxic
SESNs
p53
Nrf2
AP-1
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ROS
Oxidative strees
Figure 2: SESNs are master regulators of antioxidant defences. SESNsmay be induced upon intracellular oxidative stress by the stimulation of
transcription factors, such as p53, Nrf2, AP-1, and FoxOs. Once activated, SESNs limit ROS and oxidative stress by multiple mechanisms,
thus having a functional role in age-related diseases as well as cancer.
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levels of mitochondrial ROS lead in turn to an inﬂammatory
status through various mechanisms, including hyperactiva-
tion of the NLRP3 inﬂammasome [36]. These events have
been proposed to play a role in diverse degenerative patholo-
gies by leading to the release of mitochondrial DNA, tissue
injury, and cell death [37, 38]. Several reports indicate that
SESNs are positive regulators of autophagy in the face of
diverse environmental stresses that entail mitochondrial dys-
function [28, 39–41]. Under energetic stress, AMPK-
dependent ULK1 phosphorylation promotes autophagy by
targeting several downstream crucial autophagy eﬀectors
involved in autophagy machinery [42]. p62/SQSTM1 protein
is another important player in the autophagy process.
Indeed, p62 can function as an adaptor protein binding to
diverse autophagy substrates, such as ubiquitinated proteins,
damaged mitochondria, and the Nrf2 inhibitor Keap1, and
promotes their autophagic degradation, contributing to the
restoration of the physiological levels of ROS [43].
SESN2 binds to p62 and promotes the autophagic
degradation of p62-dependent targets, including Keap1,
thereby channelling autophagy turnover ﬂux towards func-
tionally coherent substrate sets and upregulating the tran-
scription of antioxidant genes [28]. In addition, SESN2
physically associates with ULK1 and p62 to form a func-
tional complex, favouring ULK1-mediated p62 phosphory-
lation [44]. Furthermore, SESN2 promotes the targeting of
mitochondria for recognition by the autophagic machinery,
a process described as “mitochondrial priming,” which is
further potentiated by the intrinsic capability of SESN2 to
increase ULK1 protein levels. This activity has been pro-
posed to contribute to immunological homeostasis and the
attenuation of NLRP3 hyperactivation [45]. Recently, the
role of SESN2 in the protection of renal tubules during
acute kidney injury (AKI) has been explored [46]. AKI is
a pathophysiological condition characterized by increased
mitochondrial damage that leads to oxidative stress and
apoptosis in tubular renal cells [47]. Intriguingly, autophagy
and mitophagy are induced in renal tubules in AKI through
a p53-SESN2 axis, which may constitute a protective mech-
anism of the cell [46].
5. Control of the Cellular Energetic
Metabolism by SESNs: Regulation of mTOR
and AMPK Signalling
mTORC1 is one of the major signalling nodes coupling envi-
ronmental and metabolic signals such as nutrients, growth
factors, oxygen, and stress with the control of protein synthe-
sis, lipid anabolism, and cell growth [48–50]. The recycling
and scavenging of cell components prevent de novo a cell
mass increase, and a major signal output from mTORC1
blunts autophagy [51]: mTORC1 phosphorylates ULK1 on
Ser757, disrupting its interaction with AMPK, an event
required to activate ULK1 to induce the canonical autophagic
pathway [42].
A number of studies suggest that SESNs can serve as
endogenous sensors of amino acid ﬂuctuations in the cellular
microenvironment, which are one of the central inputs
regulating mTORC1 signalling. Indeed, SESN2 induction is
necessary for cell survival during glutamine deprivation
[52]. A SESN-dependent and AMPK-independent mecha-
nism for mTORC1 inhibition might be mediated by the
interaction of SESNs with GATOR2 [53–55]. As a result of
this interaction, SESNs suppress lysosomal mTOR localiza-
tion in a Rag-dependent manner. This mechanism is thus a
potential integral component of mTORC1 regulation by
amino acid availability, connecting stress responses with
mTORC1 control [53–55]. SESNs also bind to the heterodi-
meric RagA/B-RagC/D GTPases, thus acting as GDIs for
RagA/B [56]. Accordingly, ectopic overexpression of SESNs
in HEK293T, HeLa, and MEF cell lines can inhibit amino
acid-induced translocation of Rag-GEF and mTORC1 to
the lysosome [56].
Intriguingly, two studies contribute biochemical and
biophysical evidence suggesting that SESN2 acts as a direct
sensor of leucine, which directly precludes the interaction
of SESN2 with GATOR2 [11, 13, 57]. This intriguing hypoth-
esis however has not been fully proven, and other studies
question the idea that SESN2-dependent suppression of
mTORC1 signalling is sensitive to leucine [14, 24, 53, 54,
56, 58–61], and the physical interaction between SESN2
and GATOR2 in cells can still be detected despite leucine-
rich culture conditions [53–55]. A possible scenario to recon-
cile these conﬂicting observations might rely on the eﬀect of
leucine on SESN2 being highly context-dependent. Further
studies will clarify the impact of leucine levels on the
SESN2-GATOR2 interaction across conditions. Additional
mechanisms have been proposed to explain the contribution
of SESN2 in amino acid sensing. Ye et al. reported a signal-
ling axis whereby the eIF2α kinase General Control Nonder-
epressible 2 (GCN2) is the driving sensor of amino acid
scarcity and translationally upregulates the stress transcrip-
tional regulator ATF4 to induce the expression of SESN2,
which in turn may block the lysosomal recruitment and
activation of mTORC1 [62]. Another report shows that in
response to leucine starvation, SESN2 is phosphorylated
by ULK1 thus aﬀecting mTORC1 activation [21]. In addi-
tion to being phosphorylated by ULK1, SESN2 may sustain
ULK1-dependent phosphorylation [44] and degradation of
SQSTM1/p62 [28]. Because SQSTM1 is an mTORC1 regu-
lator involved in amino acid sensing [63–65], deeper stud-
ies will be needed to clarify the functional link between
SESN2, ULK1, SQSTM1, and GATOR2 in the context of
amino acid sensing.
Notably, amino acid consumption (particularly that of
amino acids entering anaplerotic routes as alternative inter-
mediates for anabolism) and derived imbalances can consti-
tute sources of redox alteration. For example, Byun et al.
found that glutamine deprivation reduces GSH synthesis
(possibly because of a subsequent shortage in 2-oxogluta-
rate), which in turn induces SESN2 expression via the ROS-
p38 MAPK-C/EBP pathway. Of note, this study identiﬁed a
positive feedback loop between SESN2 and mTORC2 as nec-
essary to suppress mTORC1 activity in glutamine-depleted
non-small-cell lung cancer cells (NSCLC). This divergent
regulation of mTORC1 and mTORC2 by SESN2 might con-
tribute to the maintenance of redox homeostasis in the face of
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amino acid imbalance, enabling lung cancer cells to survive
under glutamine-depleted conditions, and might thus consti-
tute an attractive synergistic therapeutic target in tumours
showing such metabolic “addiction” [66].
AMPK inhibits mTORC1 through the phosphorylation
of TSC2 and raptor (two phosphor-dependent hallmarks of
mTORC1 inactivation) in response to cellular energy cues
[67–69]. Evidence indicates that SESN-dependent AMPK
induction is important for mTORC1 suppression in diverse
cellular contexts, and at least one SESN paralog, SESN2,
has been found to coimmunoprecipitate with AMPK from
tissue extracts [40, 59, 70–73]. In Drosophila, chronic TOR
activation upregulates dSESN through accumulation of
ROS. dSESN acts then as a negative feedback regulator of
TOR function. In accordance, mammalian SESNs sustain
the AMPK-TSC2 axis that integrates metabolic and stress
inputs and prevents age-associated pathologies caused by
chronic TOR activation [14]. SESN1 and SESN2 are negative
regulators of mTOR signalling through the activation of
AMPK and TSC2 phosphorylation in a p53-dependent man-
ner, and this negative regulation is required for mTORC1
signalling suppression upon DNA damage [58]. In response
to genotoxic stress, SESN2 expression is upregulated favour-
ing sustained AMPK activity by orchestrating the recruit-
ment of LKB1, as well as increasing LKB1/AMPKαβγ
expression. In addition, both AMPK and SESN2 coordinate
to suppress Akt-mTOR signalling as induced by ionizing
radiation, thus acting as radiation sensitizers in MCF7 breast
cancer cells [60]. The SESN2-dependent induction of AMPK
activity and blunting of mTORC1 seem to bear substantial
potential relevance to attenuate cell damage in conditions
associated with acute ischemia, such as hypoxic-ischemic
encephalopathy (HIE, caused by decreased oxygen and cere-
bral blood ﬂow to the brain) or cardiomyocyte ischemia
[74]. Exogenous elevation of SESN2 levels reduced the brain
infarct area and brain atrophy and improved long-term neu-
rological function in a neonatal rat model of HIE through
the induction of AMPK signalling and subsequent blockade
of mTOR signalling [75]. SESN2 also exerts neuroprotective
eﬀects during cerebral ischemia/reperfusion injury, a com-
plex pathophysiological process characterized by enhanced
levels of ROS and apoptosis, possibly by increasing mito-
chondrial biogenesis through an AMPK/PGC-1α pathway,
which attenuates oxidative stress [76, 77]. SESN2 also accu-
mulates in the heart during ischemic conditions, stabilizing
an LKB1-SESN2-AMPK complex that cannot be assembled
in SESN2-KO hearts, blunting AMPK during ischemic
injury [70]. Somewhat expected by the prominent role that
AMPK signalling has in counteracting high-glucose-induced
damage and insulin resistance, SESN2 might contribute
to the amelioration of disorders derived from metabolic
syndrome and hyperglycaemia, such as hyperglycaemia-
induced glomerular injury [73, 78], hepatosteatosis, and
insulin resistance [79]. Of note, SESN2 is induced upon
hypernutrition, and the genetic ablation of SESN2 exacer-
bates obesity-induced mTORC1-S6K activation, glucose
intolerance, insulin resistance, and hepatosteatosis in the
liver of obese mice, all of which are rescued by AMPK
pharmacological activation [80].
SESN-driven regulation of AMPK and mTOR signal-
ling also bears relevance for tumour biology. SESN2 and
SESN3 suppress NK-92 cell-mediated cytotoxic activity
on ovarian cancer cells through the induction of AMPK
and inhibition of mTORC1, pointing at its potential rele-
vance for immunotherapy in ovarian cancer [81]. SESN2
is decreased in colorectal cancer (CRC) [82], and its over-
expression limits ROS production, inhibits cell growth,
and stimulates apoptosis in CRC cell lines [83]. In addi-
tion, a protective role of SESN2 in gentamicin-induced
stress has been reported. Genetic ablation of SESN2
enhances the sensitivity of hair cells to gentamicin sug-
gesting that it may be involved in protecting sensory hair
cells against gentamicin via modulation of the AMPK/m-
TOR pathway [84]. Further supporting a functional link
between SESNs and AMPK signalling in cancer cells, GOF
mutant p53 blocks a SESN1/AMPK/PGC-1α/UCP2 axis,
increasing mitochondrial superoxide production in cancer
cells [85].
In summary, SESNs might play an important role in sig-
nalling networks linking nutrient starvation to the control of
major growth signalling and energy management networks
(i.e., mTORC1 and AMPK) (Figure 3). While a substantial
body of evidence has been gathered during the study of
tumour biology, these concepts highlight the pivotal rele-
vance of SESN-driven networks in the unfolding of processes
related to aging.
6. SESNs in Aging
Dysregulation of mTORC1 and deactivation of AMPK sig-
nalling [86, 87], associated with increased ROS production
or decreased ROS surveillance, are all closely related to hall-
marks of aging, such as loss of metabolic homeostasis and
proteostasis and reduced muscle function [88, 89]. Moreover,
since SESNs are key regulators of several of these processes,
they are also involved in aging. In Caenorhabditis elegans,
SESN1 gene mutants show ROS accumulation, muscular cell
abnormalities, and reduced lifespan [90]. At the same time,
gain-of-function mutants induced increased lifespan with
decreased muscle ROS. dSESN-/- ﬂies exhibit chronic sup-
pression of AMPK and activation of mTORC1, resulting
in fat accumulation, blood sugar elevation, and skeletal
and cardiac muscle degeneration [14]. In mice, however,
SESN2 loss-of-function mutants have normal aging, per-
haps reﬂecting diﬀerent and multifactorial mechanisms of
aging in invertebrates with respect to mammals [6]. None-
theless, SESN level is modulated by aging. Older men show
less SESN1 and SESN3 protein level in skeletal muscle and
reduced amount of the phosphorylated δ-isoform of
SESN2 compared to middle-aged and young men [15].
In the same experimental conditions, the mRNA expres-
sion of SESNs was highly upregulated, probably for com-
pensatory mechanisms.
7. SESNs and Toxic Stress Tolerance
Protection from the damage exerted by xenobiotics is para-
mount for organismal homeostasis. SESNs may have an
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important role in counteracting toxic chemicals through the
regulation of oxidative stress and autophagy induction [14,
26]. Table 1 summarizes relevant studies reporting a role
for SESNs in neuronal stress tolerance after toxic injuries.
Notably, SESN2 is expressed in the central nervous system,
and evidence supports that it is an important contributor to
antioxidant systems in the brain [23]. For example, dysregu-
lation of SESN expression in diﬀerent conditions, such as
neurodegenerative syndromes associated with advanced
HIV infection, causes increased oxidative stress [91]. More-
over, SESN protein levels were found to be higher in patients
suﬀering from Alzheimer’s and Parkinson’s diseases [92, 93],
further highlighting their role as components of oxidative
stress signatures and homeostatic surveillance in brain tissue.
The heavy metal chromium (Cr) exists in diﬀerent oxidation
states and causes harmful eﬀects on the organism. Reduction
of Cr(VI) to Cr(III) leads to various reactive Cr intermediates
and free radical generation, which results in oxidative stress
[94]. Cr(VI) was reported to inhibit acetylcholinesterase
activity in rats leading to oxidative damage to their brain
[95]. In Drosophila melanogaster, Cr(VI) also causes neuro-
nal cell death via ROS generation [96]. A recent study
reported that oxidative stress, apoptosis, and neuronal cell
death observed upon exposure of D. melanogaster larvae
to Cr(VI) were reverted by ectopic SESN overexpression.
Moreover, SESN overexpression enhances autophagy ﬂux
and decreases mTORC1 signalling/p-S6k levels in neuronal
cells, suggesting an increased catabolic activity and cellular
repair [97].
1-Methyl-4-phenylpyridinium (MPP+) is a metabolite
derived from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) that selectively destroys dopaminergic neurons in
the substantia nigra of the brain by inducing mitochondrial
dysfunction, oxidative stress, and apoptosis [98]. Because of
its powerful neurotoxic activity, it is often used as a tool for
studying Parkinson’s disease (PD) in various animal models
[99]. Of note, MMP+ induces the expression of SESN2 in
SH-SY5Y human neuroblastoma cells and this induction is
mediated by p53 [92]. Furthermore, knockdown of SESN2
enhances MPP+-induced neurotoxicity by triggering oxida-
tive stress, mitochondrial dysfunction, apoptosis, and cell
death [92]. Thus, the induction of SESN2 exerts a protective
eﬀect in neurons that might be eﬀective for the therapeutical
management of PD and other neurodegenerative diseases.
Sevoﬂurane, one of the most commonly used volatile
anaesthetics in clinical treatment, can induce neuronal
degeneration and cognitive impairment through ER stress-
driven apoptosis in neurons of aging rats [100]. Notably,
sevoﬂurane treatment induces SESN2 expression in a p53-
dependent fashion in human neuroblastoma M17 cells, and
knockdown of SESN2 blunts superoxide activity, unleashing
oxidative stress and apoptosis [88].
Accumulation of amyloid β-peptide (Aβ) in senile
plaques represents a pathological hallmark of Alzheimer’s
disease and leads to neurodegeneration by inducing cytotox-
icity and oxidative stress [101]. A recent study explored a
potential link between SESN2 and Aβ neurotoxicity. Chen
et al. reported that SESN2 expression and the autophagy
marker LC3B-II were elevated in primary rat cortical neu-
rons upon Aβ exposure. Importantly, downregulation of
SESN2 by siRNA abolished LC3B-II formation caused by
Aβ and was accompanied by neuronal death. Accordingly,
inhibition of autophagy by baﬁlomycin A1 also enhanced
Aβ neurotoxicity [41]. This indicates that SESN2 induced
by Aβ plays a protective role against Aβ neurotoxicity
through the positive regulation of autophagy.
SESN2 also features potential beneﬁcial activities on both
vascular endothelial and liver injuries, highlighting its poten-
tial as a therapeutical target in cardiovascular and liver
diseases [102, 103]. Activation of angiotensin II (AngII) sig-
nalling can trigger endothelial cell dysfunction, including
proinﬂammatory adhesion molecules, production of ROS,
and endothelial apoptosis. Again, supporting its relevant role
as a component of stress adaption signatures, SESN2 expres-
sion is increased by AngII and knockdown of SESN2
enhances AngII-induced toxicity in human umbilical vein
endothelial cells (HUVECs) [102].
Acetaminophen (APAP) is one of the most commonly
used analgesic/antipyretic drugs, and at high doses, it can
provoke acute hepatotoxicity, resulting in serious liver dam-
age and death [104]. SESN2 exerted a protective eﬀect against
APAP-induced acute liver damage by inhibiting oxidative
stress and proinﬂammatory signalling, possibly through the
inhibition of downstream MAPK pathway activation [103].
It will be interesting in the future to explore the contribution
of other pathways downstream of SESN2 that have also been
closely related mechanistically to APAP toxicity, such as
mitophagy [105].
TSC2
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Figure 3: mTORC1 regulation by SESNs and its role in cancer
progression. SESNs act as a master regulator of mTORC1 function
through activation of GATOR2 (in the presence of leucine) and
AMPK activation, thus playing a tumour-suppressive role.
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8. Conclusions
In recent years, remarkable progress has been made towards
understanding the biochemical mechanisms behind the role
of SESNs in physiopathology. Sestrins are integrated as com-
ponents of adaptive responses against a variety of cellular
stresses, including DNA damage, oxidative stress, hypoxia,
and metabolic stresses. Thus, SESNs are now recognized as
key regulators of cellular metabolism and indispensable con-
tributors to cellular homeostasis in normal physiology and
diseased states. As a positive regulator of AMPK and a
repressor of mTORC1, SESNs elicit protective eﬀects on var-
ious metabolic disorders such as diabetes and obesity, cancer,
cardiac hypertrophy, and atherosclerosis.
Importantly, modulation of SESNs can activate an
autophagic response, which in turn may lead to cancer cell
death, as well as a cytoprotective eﬀect in a manner highly
dependent by the metabolic and environmental context in
which tumour cells reside. Moreover, the potent antioxi-
dant and autophagic eﬀects orchestrated by SESNs confer
neuronal stress tolerance to toxic injuries and neuroprotec-
tion in neurodegenerative disorders that are closely linked
to oxidative stress, such as Parkinson’s disease and Alzhei-
mer’s disease. Future studies are required to further validate
such potential of SESNs as biomarkers and therapeutic tar-
gets against these disorders and to fully understand how
their multiple functions are interrelated and coordinated
at system level.
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